医药生物行业创新药周报

Investment Rating - The report assigns a "Positive" investment rating for the pharmaceutical and biotechnology industry [1]. Core Viewpoints - The report highlights that the A-share innovative drug sector saw 4 stocks rise and 22 stocks fall last week, with notable gainers including Hai Chuang Pharmaceutical-U (19.67%) and Bai Jie Shen Zhou-U (0.66%), while major losers included Shou Yao Holdings-U (-11.78%) and Rong Chang Bio (-10.00%) [1]. - In terms of R&D progress, 3 innovative drugs/improved new drugs were approved for market last week, and 11 innovative drugs/improved new drugs submitted applications for market approval [1]. - The report emphasizes the rapid development of domestic HER3 ADCs, particularly the BL-B01D1 from Bai Li Tian Heng and SHR-A2009 from Heng Rui Pharmaceutical, both of which are in Phase II clinical trials for NSCLC indications [3]. Summary by Sections Market Review - The A-share innovative drug sector experienced mixed performance, with a total of 4 stocks increasing and 22 decreasing in value last week [1]. - The Hong Kong innovative drug sector also showed similar trends, with 29 stocks rising and 16 falling [1]. Domestic R&D Progress - Three innovative drugs/improved new drugs were approved for market, while 11 submitted applications for approval [1]. - Notable approvals include the HER2 ADC drug from Heng Rui Pharmaceutical and a dual-function fusion protein for gastric cancer treatment [1]. Global R&D Progress - Several drugs received new indications, including Dupixent for chronic rhinosinusitis with nasal polyps and Keytruda for advanced malignant pleural mesothelioma [1]. - The report mentions the significant clinical trial results for patritumab deruxtecan, which showed improved progression-free survival in NSCLC patients [3]. Corporate Collaborations - Bai Li Tian Heng entered a collaboration agreement with BMS for BL-B01D1, with an upfront payment of $800 million and a potential total deal value of $8.4 billion [3]. Investment and Financing - The report discusses ongoing investment trends and financing activities within the pharmaceutical sector, highlighting the importance of strategic partnerships and funding for R&D advancements [1].